Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 6, 2013, Pages 1095-1102

  Shao, Xiaowen ^a   Mei, Wenjie ^b   Weng, Wenhao ^a   Qin, Jinlong ^a   Zhou, Jianhong ^a   Liu, Jie ^a   Cheng, Jiajing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Mir 375; Ovarian cancer; Rawq01; Ruthenium derived compound

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MIRN375 MICRORNA, HUMAN; RAWQ01; RUTHENIUM DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; IC 50; METABOLISM; MIR-375; MOUSE; NUDE MOUSE; OVARY CANCER; OVARY TUMOR; PATHOLOGY; RUTHENIUM DERIVED COMPOUND; TUMOR CELL LINE;

MIR-375; OVARIAN CANCER; RAWQ01; RUTHENIUM DERIVED COMPOUND;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MICRORNAS; OVARIAN NEOPLASMS; RUTHENIUM COMPOUNDS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883028571     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S and Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009; 112: 275-281.
3. Kaufmann SH and Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-49.
4. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107: 823-826.
5. Esquela-Kerscher A and Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
6. Hobert O. Gene regulation by transcription factors and microRNAs. Science 2008; 319: 1785-1786.
7. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673-677.
8. Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003; 113: 25-36.
9. Shahab SW, Matyunina LV, Mezencev R, Walker LD, Bowen NJ, Benigno BB and McDonald JF. Evidence for the complexity of microRNA-mediated regulation in ovarian cancer: a systems approach. PLoS One 2011; 6: e22508.
10. Hui A, How C, Ito E and Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011; 11: 500.
11. Li X, Lin R and Li J. Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci 2011; 56: 2849-2856.
12. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR and Guan XY. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33-42.
13. Anindo MI and Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg 2012; 10: 443-449.
14. Li Y, Jiang Q, Xia N, Yang H and Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res 2012; 40: 1662-1669.
15. Bergamo A, Masi A, Peacock AF, Habtemariam A, Sadler PJ and Sava G. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. J Inorg Biochem 2010; 104: 79-86.
16. Zelonka RA and Baird MC. Benzene Complexes of Ruthenium(II). Can J Chem 1972; 50: 3063-3072.
17. Nesbit CE, Tersak JM and Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
18. Fan SH, Zhang AG, Ju CC, Gao LH and Wang KZ. A triphenylamine-grafted imidazo[4,5-f][1,10]phenanthroline ruthenium(II) complex:acid-base and photoelectric properties. Inorg Chem 2010; 49: 3752-3763.
19. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J and Zhou T. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010; 20: 784-793.
20. Liu AM, Poon RT and Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010; 394: 623-627.
21. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM and Harris CC. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15: 6192-6200.
22. Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, Prystowsky MB, Schlecht NF, Segall JE and Childs G. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012; 180: 917-928.
23. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J and Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
24. Wang S, Yang D and Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30: 133-142.
25. Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006; 3: 388-398.
26. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-542.
27. Schmitt CA and Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist Updat 2001; 4: 132-134.
28. Suss-Fink G. Arene ruthenium complexes as anticancer agents. Dalton Trans 2010; 39: 1673-1688.
29. Smith GS and Therrien B. Targeted and multifunctional arene ruthenium chemotherapeutics. Dalton Trans 2011; 40: 10793-10800.
30. Hu W, Luo Q, Ma X, Wu K, Liu J, Chen Y, Xiong S, Wang J, Sadler PJ and Wang F. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes. Chemistry 2009; 15: 6586-6594.
31. Liu HK and Sadler PJ. Metal complexes as DNA intercalators. Acc Chem Res 2011; 44: 349-359.
32. Chatterjee S, Kundu S, Bhattacharyya A, Hartinger CG and Dyson PJ. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem 2008; 13: 1149-1155.